Trial Profile
A Long-Term Follow-Up Study of Oral ELND005 (AZD-103) in Subjects With Alzheimer's Disease [Extension of 700022361]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Oct 2019
Price :
$35
*
At a glance
- Drugs ELND 005 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Elan Pharmaceuticals; OPKO Health
- 09 Apr 2014 New trial record